Our Transparency commitments

AstraZeneca has a long-standing commitment to making information about our clinical research publicly available.​

We believe that being transparent about our research and development allows other researchers to access the most up to date and relevant medical evidence, as well as serving the best interests of the people and patients who use our medicines.

AstraZeneca ensures clinical research is registered according to all global requirements:

  • We register studies on other websites globally within timelines as required by country laws.

  • In the US, we register the following on the US National Library of Medicine’s website:​

    • Phase 1 to 4 interventional trials​

    • U.S. Early Access Programs​

    • Observational trials involving AZ drug, or even studies between non-AZ drug and other treatment options for clinical outcomes

    • Post Authorization Safety studies

  • In the EU, we register all phase 1-4 trials that are conducted in European Economic Area (EEA) on European Union Clinical Trial Registry or the new EU Clinical Trial information System (CTIS), prior to the first patient being enrolled in a trial.

  • All AstraZeneca sponsored interventional and above mentioned observational clinical trials are listed on our dedicated clinical trials website, astrazenecaclinicaltrials.com.

Our vision is to be trusted for clinical trial transparency by regulators, investigators, participants, and society.

Our vision is to be trusted for clinical trial transparency by regulators, investigators, participants, and society.

We deliver Clinical Trial Transparency by making clinical trial data, documents and results accessible to all within the framework of global regulations, policies, and industry best practices, and ensuring patient privacy and trial integrity. Our clinical trial transparency framework is guided by the Declaration of Helsinki and the EFPIA (European Federation of Pharmaceutical Industries and Associations) and PhRMA (Pharmaceutical Research and Manufacturers of America) joint Principles for Responsible Clinical Trial Data Sharing. 

We meet our transparency commitments by publishing information on the registration, results and health authority submission activities relating to new and ongoing AstraZeneca sponsored clinical trials for all products in all phases, including marketed medicines, drugs in development and drugs whose further development has been discontinued.